Correlation of epidermal growth factor receptor mutation, immunohistochemistry, and fluorescence in situ hybridization in esophageal squamous cell carcinoma

Journal of the Medical Association of Thailand

Volumn 92, Issue 9, 2009, Pages 1136-1142

  Sunpaweravong, Patrapim ^a   Suwiwat, Supaporn ^a   Sunpaweravong, Somkiat ^a   Puttawibul, Puttisak ^a   Mitarnun, Winyou ^a  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

Author keywords

Epidermal growth factor receptor; Esophageal; Fluorescence in situ hybridization; Immunohistochemistry; Mutation; Squamous cell carcinoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; PROTEIN TYROSINE KINASE;

AGAR GEL ELECTROPHORESIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE MUTATION; GENE NUMBER; GENE SEQUENCE; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; POLYMERASE CHAIN REACTION; PROTEIN DOMAIN; PROTEIN EXPRESSION;

CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; GENES, ERBB-1; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 70349270639     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer incidence in five continents. Vol 8. Lyon: International Agency for Research and Cancer (IARC); 2002.
2. Cragg MS, Kuroda J, Puthalakath H, Huang DC, Strasser A. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med 2007; 4: 1681-1689 (Pubitemid 350035457)
3. Hara F, Aoe M, Doihara H, Taira N, Shien T, Takahashi H, et al. Antitumor effect of gefitinib ('Iressa') on esophageal squamous cell carcinoma cell lines in vitro and in vivo. Cancer Lett 2005; 226: 37-47. (Pubitemid 40943428)
4. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005; 353: 172-187 (Pubitemid 41058349)
5. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352: 786-792 (Pubitemid 40271173)
6. Yatabe Y, Hida T, Horio Y, Kosaka T, Takahashi T, Mitsudomi T. A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer. J Mol Diagn 2006; 8: 335-341 (Pubitemid 44063810)
7. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290: 2149-2158 (Pubitemid 37432975)
8. Shepherd FA, Rodrigues PJ, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-132 (Pubitemid 41058344)
9. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139 (Pubitemid 38637993)
10. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500 (Pubitemid 38720929)
11. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel- Reid S, Squire J, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005; 353: 133-144 (Pubitemid 41058345)
12. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005; 97: 643-655 (Pubitemid 40812628)
13. Sakurada A, Shepherd FA, Tsao MS. Epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer: impact of primary or secondary mutations. Clin Lung Cancer 2006; 7(Suppl 4): S138-44. (Pubitemid 44056782)
14. Sunpaweravong P, Sunpaweravong S, Puttawibul P, Mitarnun W, Zeng C, Baron AE, et al. Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 2005; 131: 111-119 (Pubitemid 40192936)
15. Sueoka N, Sato A, Eguchi H, Komiya K, Sakuragi T, Mitsuoka M, et al. Mutation profile of EGFR gene detected by denaturing high-performance liquid chromatography in Japanese lung cancer patients. J Cancer Res Clin Oncol 2007; 133: 93-102. (Pubitemid 44950241)
16. Miller VA. EGFR mutations and EGFR tyrosine kinase inhibition in non-small cell lung cancer. Semin Oncol Nurs 2008; 24: 27-33.
17. Hanawa M, Suzuki S, Dobashi Y, Yamane T, Kono K, Enomoto N, et al. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer 2006; 118: 1173-1180 (Pubitemid 43185604)
18. Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, Meijer GA, Vervenne WL, Richel DJ, et al. Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol 2006; 24: 1612-1619 (Pubitemid 46638785)
19. Dragovich T, McCoy S, Fenoglio-Preiser CM, Wang J, Benedetti JK, Baker AF, et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006; 24: 4922-4927 (Pubitemid 46630921)
20. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005; 353: 2012-2024 (Pubitemid 41609094)
21. Barber TD, Vogelstein B, Kinzler KW, Velculescu VE. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med 2004; 351: 2883. (Pubitemid 40051921)
22. Rich JN, Rasheed BK, Yan H. EGFR mutations and sensitivity to gefitinib. N Engl J Med 2004; 351: 1260-1261